IMP dehydrogenase: inhibition by the anti-leukemic drug, tiazofurin. 1989

Y Yamada, and Y Natsumeda, and Y Yamaji, and H N Jayaram, and G J Tricot, and R Hoffman, and G Weber
Laboratory for Experimental Oncology, Indiana University School of Medicine, Indianapolis 46223.

Tiazofurin through its active metabolite thiazole-4-carboxamide adenine dinucleotide (TAD) inhibits IMP dehydrogenase, the rate-limiting enzyme of GTP biosynthesis. IMP dehydrogenase activity in human leukemic cell extracts (33.4 +/- 0.1 nmol/h/mg protein) was increased 11-fold compared to normal leukocytes (3.1 +/- 0.5). Km values for IMP and NAD+ of leukemic IMP dehydrogenase were 22.7 and 44.0 microM, respectively. XMP inhibited competitively with IMP and noncompetitively with NAD+. NADH exerted mixed type inhibition with respect to both IMP and NAD+. The inhibitory pattern of TAD was quite similar to that of NADH; however, the affinity of TAD to leukemic IMP dehydrogenase (Ki = 0.1 microM) was three orders of magnitude higher than the natural product NADH (Ki = 150 microM). These results contribute to an understanding of the mechanism of action of tiazofurin in the treatment of leukemia.

UI MeSH Term Description Entries
D007168 IMP Dehydrogenase An enzyme that catalyzes the dehydrogenation of inosine 5'-phosphate to xanthosine 5'-phosphate in the presence of NAD. EC 1.1.1.205. Inosinic Acid Dehydrogenase,Inosine-5-Monophosphate Dehydrogenase,Acid Dehydrogenase, Inosinic,Dehydrogenase, IMP,Dehydrogenase, Inosine-5-Monophosphate,Dehydrogenase, Inosinic Acid,Inosine 5 Monophosphate Dehydrogenase
D007658 Ketone Oxidoreductases Oxidoreductases that are specific for KETONES. Oxidoreductases, Ketone
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009249 NADP Nicotinamide adenine dinucleotide phosphate. A coenzyme composed of ribosylnicotinamide 5'-phosphate (NMN) coupled by pyrophosphate linkage to the 5'-phosphate adenosine 2',5'-bisphosphate. It serves as an electron carrier in a number of reactions, being alternately oxidized (NADP+) and reduced (NADPH). (Dorland, 27th ed) Coenzyme II,Nicotinamide-Adenine Dinucleotide Phosphate,Triphosphopyridine Nucleotide,NADPH,Dinucleotide Phosphate, Nicotinamide-Adenine,Nicotinamide Adenine Dinucleotide Phosphate,Nucleotide, Triphosphopyridine,Phosphate, Nicotinamide-Adenine Dinucleotide
D001752 Blast Crisis An advanced phase of chronic myelogenous leukemia, characterized by a rapid increase in the proportion of immature white blood cells (blasts) in the blood and bone marrow to greater than 30%. Blast Phase,Blast Crises,Blast Phases,Crises, Blast,Crisis, Blast,Phase, Blast,Phases, Blast
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000227 Adenine Nucleotides Adenine Nucleotide,Adenosine Phosphate,Adenosine Phosphates,Nucleotide, Adenine,Nucleotides, Adenine,Phosphate, Adenosine,Phosphates, Adenosine
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy

Related Publications

Y Yamada, and Y Natsumeda, and Y Yamaji, and H N Jayaram, and G J Tricot, and R Hoffman, and G Weber
January 1989, Advances in enzyme regulation,
Y Yamada, and Y Natsumeda, and Y Yamaji, and H N Jayaram, and G J Tricot, and R Hoffman, and G Weber
October 1992, Gynecologic oncology,
Y Yamada, and Y Natsumeda, and Y Yamaji, and H N Jayaram, and G J Tricot, and R Hoffman, and G Weber
February 1997, Cytometry,
Y Yamada, and Y Natsumeda, and Y Yamaji, and H N Jayaram, and G J Tricot, and R Hoffman, and G Weber
January 1992, Life sciences,
Y Yamada, and Y Natsumeda, and Y Yamaji, and H N Jayaram, and G J Tricot, and R Hoffman, and G Weber
December 1985, Molecular pharmacology,
Y Yamada, and Y Natsumeda, and Y Yamaji, and H N Jayaram, and G J Tricot, and R Hoffman, and G Weber
April 1984, The Journal of biological chemistry,
Y Yamada, and Y Natsumeda, and Y Yamaji, and H N Jayaram, and G J Tricot, and R Hoffman, and G Weber
April 1990, Journal of medicinal chemistry,
Y Yamada, and Y Natsumeda, and Y Yamaji, and H N Jayaram, and G J Tricot, and R Hoffman, and G Weber
July 2009, Chemical reviews,
Y Yamada, and Y Natsumeda, and Y Yamaji, and H N Jayaram, and G J Tricot, and R Hoffman, and G Weber
January 2003, Nucleic acids research. Supplement (2001),
Y Yamada, and Y Natsumeda, and Y Yamaji, and H N Jayaram, and G J Tricot, and R Hoffman, and G Weber
July 1999, Current medicinal chemistry,
Copied contents to your clipboard!